Select Language

Complement Factor D

Complement Factor D Overview

English Name	Complement factor D	Approved Drugs	1
Drugs in Clinical Trials	5	Target Synonym	EC 3.4.21，EC 3.4.21');，C3 Convertase Activator，ADIPSIN，D Component Of Complement (Adipsin)，PFD，Complement Factor D Preproprotein，Complement Factor D (Adipsin)，EC 3.4.21.46，ADN，CFD，Properdin factor D，DF，Complement factor D，EC:3.4.21.46
Highest Development Stage	Approved

English Name	Complement factor D
Target Synonym	EC 3.4.21，EC 3.4.21');，C3 Convertase Activator，ADIPSIN，D Component Of Complement (Adipsin)，PFD，Complement Factor D Preproprotein，Complement Factor D (Adipsin)，EC 3.4.21.46，ADN，CFD，Properdin factor D，DF，Complement factor D，EC:3.4.21.46
Approved Drugs	1
Drugs in Clinical Trials	5
Highest Development Stage	Approved

Complement Factor D Product List

Product Category
Protein (3)
Product Status
Launched (3)
Species
Human (2)Cynomolgus / Rhesus macaque (1)
Tag
His Tag (2)Fc Tag (1)
Conjugate
Unconjugated (3)

Cat. No.	Species	Host	Product Description
HOT CFD-H5256	Human	HEK293	Human Complement Factor D / CFD Protein, Fc Tag
HOT CFD-H52H8	Human	HEK293	Human Complement Factor D / CFD Protein, His Tag (active enzyme)
CFD-R52H3	Cynomolgus / Rhesus macaque	HEK293	Rhesus macaque / Cynomolgus Complement Factor D / CFD Protein, His Tag (active enzyme)

Total: 3

Complement Factor D Background

Complement factor D (CFD) is also known as Adipsin, C3 convertase activator, Properdin factor D (PFD), which contains one peptidase S1 domain and belongs to the peptidase S1 family. CFD / Adipsin cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. CFD / Adipsin is a serine protease that stimulates glucose transport for triglyceride accumulation in fats cells and inhibits lipolysis. Defects in CFD / Adipsin are the cause of complement factor D deficiency which predisposes to invasive meningococcal disease.

Complement Factor D Synonyms

CFD,Adipsin,PFD,DF,Complement factor D

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
BCX-9930	BCX-9930	Phase 2 Clinical	Biocryst Pharmaceuticals Inc	Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulonephritis	Details
Vemircopan	ACH-0145228; ACH-5228; ALXN-2050	Phase 1 Clinical	Achillion Pharmaceuticals Inc	Myasthenia Gravis; Renal Insufficiency; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Lupus Nephritis; Hepatic Insufficiency	Details
ACH-5548	ACH-5548; ACH-0145548	Phase 1 Clinical	Achillion Pharmaceuticals Inc	Autoimmune Diseases	Details
BCX-10013	BCX-10013	Phase 1 Clinical	Biocryst Pharmaceuticals Inc	Hemoglobinuria, Paroxysmal	Details
ALXN-2080	ALXN-2080	Phase 1 Clinical	Alexion Pharmaceuticals Inc		Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Danicopan	ACH-4471; ACH-0144471; ACH-CFDIS; ALXN-2040	Approved	Achillion Pharmaceuticals Inc	VOYDEYA, Voydeya	Japan	Hemoglobinuria, Paroxysmal	Alexion Pharmaceuticals Inc	2024-01-18	Hemolysis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Glomerulonephritis, Membranoproliferative; Geographic Atrophy; Hepatic Insufficiency; Glomerulonephritis	Details